DrugPatentWatch Database Preview
Drugs in Development Information for RDEA3170
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for RDEA3170?
RDEA3170 is an investigational drug.
There have been 15 clinical trials for RDEA3170.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 28th 2017.
The most common disease conditions in clinical trials are Gout, Hyperuricemia, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Ardea Biosciences, Inc., AstraZeneca, and Contract Research Organization: USA.
There are seven US patents protecting this investigational drug and one hundred and fifteen international patents.
Summary for RDEA3170
| US Patents | 7 |
| International Patents | 115 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-05-28) |
| Vendors | 23 |
Recent Clinical Trials for RDEA3170
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA | Analytical Laboratory (Pharmacokinetic Sample Analysis): USA | Phase 2 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA | Clinical Laboratory: USA | Phase 2 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA | Contract Research Organization: USA | Phase 2 |
Clinical Trial Summary for RDEA3170
Top disease conditions for RDEA3170
Top clinical trial sponsors for RDEA3170
US Patents for RDEA3170
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RDEA3170 | Start Trial | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | Start Trial |
| RDEA3170 | Start Trial | URAT1 inhibitor | Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP) | Start Trial |
| RDEA3170 | Start Trial | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc. (San Diego, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RDEA3170
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RDEA3170 | Australia | 2016236669 | 2035-03-24 | Start Trial |
| RDEA3170 | Canada | 2980484 | 2035-03-24 | Start Trial |
| RDEA3170 | China | 106008340 | 2035-03-24 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
